Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

TriSalus Life Sciences, Inc. (TLSI) had Revenue of $29.43M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$29.43M
Net Income	$-33.23M
Cost of Goods Sold	$4.10M
Gross Profit	$25.33M
Operating Expenses	$65.60M
Operating Income	$-36.16M
Non-Operating Income/Expense	$6.13M
Pre-Tax Income	$-30.04M
Normalized Pre-Tax Income	$-30.04M
Income after Taxes	$-30.05M
Income from Continuous Operations	$-30.05M
Consolidated Net Income/Loss	$-30.05M
Normalized Income after Taxes	$-30.05M
EBIT	$-36.16M
EBITDA	$-34.81M
Weighted-Average Shares Outstanding (Basic)	25.33M
Weighted-Average Shares Outstanding (Diluted)	25.33M
Earnings per Share (EPS) (Basic)	$-1.31
Earnings per Share (EPS) (Diluted)	$-1.31
Balance Sheet Financials
Current Assets	$20.67M
Property, Plant, and Equipment	$1.67M
Long-Term Assets	$3.30M
Total Assets	$23.97M
Current Liabilities	$10.23M
Long-Term Debt	$22.08M
Long-Term Liabilities	$39.64M
Total Liabilities	$49.87M
Common Equity	$-25.89M
Tangible Shareholders Equity	$-25.89M
Shareholders Equity	$-25.89M
Common Shares Outstanding	31.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-40.84M
Cash Flow from Investing Activities	$-0.34M
Cash Flow from Financial Activities	$37.94M
Beginning Cash	$12.13M
End Cash	$8.88M
Increase/Decrease in Cash	$-3.25M
Stock-Based Compensation	$5.44M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.02
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-5.80
Debt to Equity Ratio	-0.85
Gross Margin	86.06%
Operating Margin	-122.88%
EBIT Margin	-122.88%
EBITDA Margin	-118.27%
Pre-Tax Profit Margin	-102.07%
Profit Margin	-112.92%
Free Cash Flow	$-41.19M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	1.23
Inventory Turnover	1.01
Receiveable Turnover	5.79
Days Sales in Receivables	63.09
Return on Equity	116.03%
Return on Tangible Equity	116.03%
Return on Assets	-125.34%
Return on Investments	788.58%
Book Value Per Share	$-0.83
Free Cash Flow per Share	$-1.63
Operating Cash Flow per Share	$-1.61

Data from Zacks Investment Research, Inc.